- Current report filing (8-K)
December 21 2010 - 4:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 15, 2010
REGENERX BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-15070
|
|
52-1253406
|
(State or other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
15245 Shady Grove Road, Suite 470, Rockville, MD
|
|
20850
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(301) 208-9191
|
Not Applicable
|
(Former name or former address if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
As previously reported, on October 26, 2010, RegeneRx Biopharmaceuticals, Inc. (the Company) received a notice from
the staff of the NYSE Amex (the Exchange) stating that the Company had failed to regain compliance with the
Exchanges continued listing standards and that, accordingly, the Companys common stock was subject to a delisting
proceeding. Primarily, the Exchange advised the Company that it was not in compliance with Section 1003(a)(iii) of
the Exchanges Company Guide because the Companys stockholders equity was less than $6,000,000. In accordance with
Sections 1009(d) and 1203 of the Exchanges Company Guide, the Company appealed the determination and requested a
hearing before the Exchanges Listing Qualifications Panel. The hearing was scheduled to occur on December 17, 2010.
On December 15, 2010, the Company notified the Exchange of its intent to withdraw the request for a hearing, and the
Exchange notified the Company that the Companys common stock would be suspended from the Exchange with the open of
trading on December 23, 2010. The Companys common stock is
expected to be quoted on the OTC Bulletin Board as of December 23,
2010. The Company intends to continue to file periodic reports with the SEC pursuant to the requirements of the Securities
Exchange Act of 1934, as amended.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
REGENERX BIOPHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
By:
|
|
/s/ J.J. Finkelstein
|
|
|
|
|
|
|
|
|
|
J.J. Finkelstein
|
|
|
|
|
President and Chief Executive Officer
|
Date: December 21, 2010
3
Regenerx Biopharm In (AMEX:RGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Regenerx Biopharm In (AMEX:RGN)
Historical Stock Chart
From Oct 2023 to Oct 2024